Extended-release naltrexone (XR-NTX, also known as Vivitrol) is the newest FDA-approved medication for opioid and alcohol use disorders. It is the result of decades of federal and industry research into long-acting, safe, effective addiction medications. Naltrexone, a mu-opioid receptor antagonist, blocks many of the reinforcing effects of opioids (e.g., heroin, oxycodone) and alcohol, which in turn reduces illicit opioid and heavy alcohol use in treated individuals. A growing body of literature supports the feasibility and effectiveness of XR-NTX treatment among justice-involved populations.

Author:

Joshua D. Lee, M.D., M.Sc., Assistant Professor, NYU School of Medicine

Date: 2013